A handful of technical analysis tools are suggesting that Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) overall gets 56.% Sell rating. The stock is also flashing a Hold from the Barchart TrendSpotter trading system. Traders hoping to speculate on the AERI’s short-term trajectory should know that short terms indicators for the stock averaged 40% Sell with an average daily trading volume over the past 20 days at 623880 shares. AERI stock has overall a 0.75% Sell signal considering medium term indicators and the 50-day average daily volume remained almost 575992 shares. It’s also worth noting that the stock, whose average daily volume over the 100 days prior to this writing was 579028 shares, is 67% Sell on the basis of long term indicators.
The share price is currently staying around the first support level of $38.72. Below this, the next support is placed in the zone of $37.15. Till the time, the AERI stock trades above this level, bulls have nothing to fear. On momentum oscillators front, ‘RSI’ has touched 37.43 on daily chart, which may remain a cause for comfort. If the price breaks below $37.15 level on closing basis, then we may see more profit booking and the stock may show further weakness. On the flipside, hitting the $41.26 mark may result into a pull-back move towards $42.23 level.
Aerie Pharmaceuticals, Inc. (AERI) is projected to climb by 106.2 percent over the next 12 months, according to price target estimates compiled by finviz. Meanwhile, they have set a $105 price as 12-month high target. This represents a whopping 160.55 percent increase from where shares are trading today. The 12-month median price target assigned by the analysts stands at $84, which represents a return potential of 108.44 percent when compared to the closing price of the stock of $40.3 on Monday, February 11. The lowest price target for the stock is $64 — slightly more than 58.81 percent from AERI’s current share price.
Here’s a rundown of insider trading activity for sense of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). The earliest insider trade took place on 02/01/2019. Kopczynski Casey C. parted with a total of 11 thousand shares of company at average share price of $46.17. The total for the sales was set at $507.87 thousand. After this transaction, the Chief Scientific Officer account balance stood at 95.74 thousand shares. The stock lost -12.71 percent since that insider sale. On 01/02/2019, Kopczynski Casey C., Chief Scientific Officer, sold 11 thousand shares at a price per share of $35.21. This removed 387.31 thousand shares from the insider’s fortune and the stock saw a 14.46 percent rally in value since the news became public. This transaction left 106.74 thousand shares in the Chief Scientific Officer account. On 12/03/2018, Chief Scientific Officer Kopczynski Casey C. performed a sale transaction worth $437.91 thousand. This sale at $39.81 each has eliminated 11 thousand shares from the insider’s portfolio position. Meanwhile, shares have recorded 1.23 percent increase since the transaction was reported. The insider now is left with 117.74 thousand shares remaining in the account. Cagle Gerald D., who performs the Director job, bought 2 thousand shares for $83.5 thousand. The acquisition occurred on 11/16/2018 was priced at $41.75 per share. The share price plunged -3.47 percent since the reporting date. Cagle Gerald D. now left with a stake of 19.8 thousand AERI stock worth $797.94 thousand after the insider buying.
AERI shares dropped -0.09 points or -0.22 percent on Monday to $40.3 with a light trade volume of 2.387 million shares. After opening the session at $40.59, the shares went as high as $40.6456 and as low as $38.11, the range within which the stock’s price traded throughout the day. The firm is left with a market cap of $1.95 billion and now has 48.47 million shares outstanding. Aerie Pharmaceuticals, Inc. (AERI) stock has lost -3.08 percent of market value in 21 trading days.
Analysts at Needham lifted target price for shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) but repeated their Buy recommendation for the stock in their opinion released on July 13. The price target has been raised from $76 to $86.
AERI stock has a trailing 3-year beta of 1.01, offering the possibility of a higher rate of return, but also posing more risk. The portion of a company’s profit allocated to each outstanding share of common stock was -$6.02 a share in the trailing twelve months. The stock’s value has surged 11.63 percent year to date (YTD) against a decline of -24.74 percent in 12 month’s time. The company’s shares still trade -46.09 percent away from its 1-year high of $74.75 and 25.23 percent up from 52-week low of $32.18. The average consensus rating on the company is 1.7, on a scale where 5 equates to a unanimous sell rating. In short, the mean analyst recommendations are calling this stock a buy.
Shares of Aerie Pharmaceuticals, Inc. (AERI) are trading at a P/E ratio of 0 times earnings reported for the past 12 months. The industry AERI operates in has an average P/E of 87.64. Its P/E ratio went as low as 0X and as high as 0 over the 5-year span. Further, it is sporting a 201.38 on the Price-to-Sales ratio. Compare this with the industry average P/S of 51.22. 97.3 percent is the gross profit margin for Aerie Pharmaceuticals, Inc. and operating margin sits at 0 percent. Along with this, the net profit margin is 0 percent.